
GT Biopharma GTBP
$ 0.41
-8.07%
Annual report 2025
added 03-02-2026
GT Biopharma Cash Conversion Cycle 2011-2026 | GTBP
Quarterly Cash Conversion Cycle GT Biopharma
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -6.97 K | -1.97 K | - | - | -646 | -6.76 K | -1.11 K | - | -2.34 K | - | -73.6 K | - | -9.06 K | -4.83 K | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -646 | -73.6 K | -11.9 K |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Veracyte
VCYT
|
32.2 | $ 30.92 | -5.73 % | $ 2.43 B | ||
|
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | ||
|
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | ||
|
Albireo Pharma
ALBO
|
-1.55 K | - | -0.23 % | $ 916 M | ||
|
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | ||
|
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | ||
|
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M | ||
|
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K | ||
|
bluebird bio
BLUE
|
-54.4 | - | - | $ 546 M | ||
|
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - | ||
|
Avid Bioservices
CDMO
|
85.5 | - | - | $ 789 M | ||
|
Advaxis
ADXS
|
-143 K | - | -9.65 % | $ 45.9 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
72.3 | $ 12.67 | -9.24 % | $ 1.92 B | ||
|
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B | ||
|
Alnylam Pharmaceuticals
ALNY
|
46.6 | $ 321.51 | -2.03 % | $ 42.1 B | ||
|
BioDelivery Sciences International
BDSI
|
340 | - | -4.8 % | $ 255 M | ||
|
Cara Therapeutics
CARA
|
52.4 | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
3.1 | - | - | $ 3.74 B | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
-193 | $ 1.09 | - | $ 22.4 M | ||
|
Equillium
EQ
|
16.6 | $ 1.91 | -7.28 % | $ 109 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
205 | $ 19.46 | -0.36 % | $ 910 M | ||
|
Amarin Corporation plc
AMRN
|
213 | $ 14.23 | -2.97 % | $ 5.91 B | ||
|
CRISPR Therapeutics AG
CRSP
|
1.1 K | $ 45.99 | -3.28 % | $ 4.14 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
50 | $ 4.33 | -2.81 % | $ 830 M | ||
|
Brickell Biotech
BBI
|
149 | - | -5.38 % | $ 6.06 M |